Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G2A | P14555 | 2/20 | 0.51 |
| ▸ | THRA | P10827 | 5/20 | 0.46 |
| ▸ | THRB | P10828 | 5/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | GLRA1 | P23415 | 1/20 | 0.44 |
| ▸ | PLA2G4B | P0C869 | 1/20 | 0.43 |
| ▸ | BLM | P54132 | 1/20 | 0.43 |
| ▸ | RXRA | P19793 | 1/20 | 0.42 |
| ▸ | RARB | P10826 | 3/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4890126 | 0.94 | GLRA1 (0.46) | PLA2G2ATHRATHRBTP53TSHR | |
| SCHEMBL4890148 | 0.81 | ALDH1A1 (0.43) | THRATHRBTSHRGLRA1RXRA | |
| SCHEMBL4898800 | 0.80 | THRA (0.63) | PLA2G2ATHRATHRBTP53TSHR | |
| SCHEMBL9402785 | 0.80 | PLA2G2A (0.78) | PLA2G2ATP53TSHRPLA2G4BBLM | |
| SCHEMBL4891284 | 0.79 | PLA2G2A (0.54) | PLA2G2ATHRATHRBTP53TSHR | |
| SCHEMBL4586960 | 0.76 | RXRA (0.56) | PLA2G2ATHRATHRBTP53TSHR | |
| SCHEMBL4892271 | 0.75 | THRB (0.64) | THRATHRBGLRA1PLA2G4BRXRA | |
| SCHEMBL9402738 | 0.73 | SMPD1 (0.68) | PLA2G2ATHRATHRBTP53TSHR | |
| SCHEMBL6908862 | 0.73 | RXRA (0.56) | THRATHRBRXRARARB | |
| SCHEMBL25788148 | 0.73 | MEN1 (0.42) | PLA2G2ATHRATHRBTP53TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080027096-A1 | Novel Pharmaceutical Compositions | KARO BIO AB (SE) | 2008-01-31 | — | — | US | disclosed |
| EP-1729756-A2 | NOVEL PHARMACEUTICAL COMPOSITIONS | KARO BIO AB (SE) | 2006-12-13 | — | — | EP | disclosed |
| WO-2005094810-A2 | NOVEL PHARMACEUTICAL COMPOSITIONS | KARO BIO AB (SE) | 2005-10-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080027096-A1 | Novel Pharmaceutical Compositions | AR, NR5A1, CYP17A1 | PLA2G2A 2747/4885THRA 559/4885THRB 792/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.